STAT+: Lilly’s next-gen obesity drug delivers major weight loss in Phase 3 trial, but with many discontinuations
Eli Lilly’s next-generation obesity drug led to what appears to be the most weight loss seen so far in a late-stage trial, but rates of side effects were high and many participants discontinued the treatment, including people who felt they were losing too much weight. In a 68-week Phase 3 study of patients with obesity […]
STAT+: Wave’s ‘gym bro’ obesity drug is story over substance
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I’m just back from the ASH meeting in Orlando, so a shorter-than-normal newsletter this week. “Mean Adam” is also back. You’ll see below. Continue to STAT+ to read the full story…
Life, Vol. 15, Pages 1893: The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials
Life, Vol. 15, Pages 1893: The Role of Glucagon-like Peptide-1 Receptor Agonists in Alzheimer’s and Parkinson’s Disease: A Literature Review of Clinical Trials Life doi: 10.3390/life15121893 Authors: Joanna Pilśniak Julia Węgrzynek-Gallina Błażej Bednarczyk Aleksandra Buczek Aleksandra Pilśniak Tomasz Chmiela Agnieszka Jarosińska Joanna Siuda Michał Holecki Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the […]
Weight loss drugs for pets: Everything you need to know
Okava Pharmaceuticals, a biopharmaceutical company, has launched a pilot study of a GLP-1 drug for cats with obesity
Feel Like Everyone Is On GLP-1s? It’s About More Than Weight Loss
The GLP-1 craze isn’t going anywhere, but it is changing course.
Glucose-lowering drugs may reduce risk of developing epilepsy
A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.
GLP1-RA IN PREGNANCY – JOURNAL CLUB.pptx
GLP1 RA use in pregnancy
GLP-1 diabetes drugs linked to lower epilepsy risk in large study
A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published in Neurology.
Bone Fractures Down With GLP-1 Drugs in the Picture
(MedPage Today) — Beyond their established cardiometabolic benefits, GLP-1 receptor agonists also may be tied to improved bone health, based on an observational report. Adults with type 2 diabetes on GLP-1 agonists tended to have small but significant…
GLP-1 Receptor Agonists May Have Little or No Effect on Obesity-Related Cancers
WEDNESDAY, Dec. 10, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) seem to have little or no effect on obesity-related cancers, according to a review published online Dec. 8 in the Annals of Internal Medicine. Albert Ko, M.D., from…